January 27, 2009 / 1:26 PM / 9 years ago

NICE to review how it values new drugs

LONDON (Reuters) - The healthcare spending watchdog NICE said it was reviewing how it values new technologies, a week after an industry report called for such a move.

The study, which will report in time for NICE’s July board meeting, will be led by Ian Kennedy, professor of health law, ethics and policy at University College London.

NICE’s announcement on Tuesday followed an industry report published last week calling for an enquiry to assess the long-term impact of NICE on the cost and the uptake of drugs, along with a series of tax breaks and other measures to support the crisis-hit biotechnology industry.

Industry body BioIndustry Association said it would repeat the calls on Tuesday afternoon at a summit with Prime Minister Gordon Brown, Business Secretary Peter Mandelson and Health Secretary Alan Johnson.

The meeting, organised by the Association of the British Pharmaceutical Industry, has been set up to suggest ways the government can support the life sciences sector.

It is to be attended by representatives from leading pharmaceutical companies including GlaxoSmithKline and Pfizer.

Reporting by Ben Deighton; editing by Dan Lalor

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below